Patrick J. Heron - 29 May 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: Director
Issuer ticker: MIRM
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 19:39:26 UTC
Prior SEC filing: 23 May 2025
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Patrick J. Heron filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 02 Jun 2025.

Key facts

This page summarizes Patrick J. Heron's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 02 Jun 2025, 19:39.

Change

Previous filing in this sequence was filed on 23 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001365617 Primary reporting owner

Heron Patrick J

Relationship: Director
Address: C/O MIRUM PHARMACEUTICALS, INC., 989 E. HILLSDALE BLVD., SUITE 300, FOSTER CITY
Signature: /s/ Judit Ryvkin, Attorney-in-Fact
Signature date: 02 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,703
Change %
Price
Shares after: 5,703
Date: 29 May 2025
Ownership: Direct
Footnotes: F1

MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,566,912
Date: 29 May 2025
Ownership: By Frazier Life Sciences IX, L.P.
Footnotes: F2

MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 168,672
Date: 29 May 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -5,703
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,703
Exercise price
Footnotes: F1, F4

MIRM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,268
Change %
Price: $0.000000
Shares after: 6,268
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,268
Exercise price: $44.00
Footnotes: F5

MIRM transaction Derivative

Deferred Stock Units

Award

Transaction value: $0
Shares: +3,977
Change %
Price: $0.000000
Shares after: 3,977
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,977
Exercise price
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (or its cash equivalent, at the discretion of the Issuer).

Footnote F2

The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F3

The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F4

The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.

Footnote F5

The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.

Footnote F6

Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.